Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2005

Beutel Gernot, Glen Hilary, Schöffski Patrick, Chick Jon, Gill Stan, Cassidy James, Twelves Chris

Abstract excerpt

PURPOSE: OSI-7904L is a liposomal formulation of a potent noncompetitive thymidylate synthase inhibitor (TSI) that does not require polyglutamation for activity. This phase I study was done to establish the safety, tolerability, maximum tolerated dose, recommended dose, and pharmacokinetics of OSI-7904L in patients with advanced solid tumors refractory to standard therapy. DESIGN: OSI-7904L was given as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Glutarates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homocysteine

Share to Infusions, Intravenous

Share to Liposomes

Share to Maximum Tolerated Dose

Share to Sepsis

Share to Thymidylate Synthase

Source

Identifiers

PMID: 16061865
DOI: 10.1158/1078-0432.CCR-05-0104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.PMID 16061865Read ↗

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.Semantic proximity Read ↗

Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.Semantic proximity Read ↗

Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.Semantic proximity Read ↗

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.Semantic proximity Read ↗

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.Semantic proximity Read ↗

Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?Semantic proximity Read ↗

2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337Semantic proximity Read ↗

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracilSemantic proximity Read ↗

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.Semantic proximity Read ↗

Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.